Desmoglein-3 Antibody (216519) [Unconjugated]

Western blot shows lysates of human skin cancer (squamous cell carcinoma) tissue. PVDF membrane was probed with 0.5 µg/mL of Mouse Anti-Human Desmoglein-3 Monoclonal Antibody (Catalog # MAB1720) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for Desmoglein-3 at approximately 130 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Desmoglein-3 was detected in immersion fixed paraffin-embedded sections of human squamous cell carcinoma using Mouse Anti-Human Desmoglein-3 Monoclonal Antibody (Catalog # MAB1720) at 8 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was localized to plasma membranes of keratinocytes. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

• Reactivity: Hu
• Applications: WB, IHC
• Clone: 216519
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

Desmoglein-3 Antibody (216519) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Desmoglein-3
  Glu50-Arg615
  Accession # P32926
• Specificity: Detects human Desmoglein-3 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human (rh) Desmoglein-1, rhDesmoglein-2, or rhCadherin-17 is observed.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: DSG3
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 8-25 ug/mL
  • Western Blot 0.5 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Desmoglein-3 Antibody (216519) [Unconjugated]

• Cadherin family member 6
• CDHF6
• CDHF6130-kD pemphigus vulgaris antigen
• desmoglein 3 (pemphigus vulgaris antigen)
• desmoglein 3
• Desmoglein3
• Desmoglein-3
• DKFZp686P23184,130 kDa pemphigus vulgaris antigen
• DSG3
• pemphigus vulgaris antigen
• PVA

Background

Desmoglein-3, also known as pemphigus vulgaris antigen (PVA), is a 130 kDa transmembrane glycoprotein that belongs to the cadherin family of calcium dependent adhesion molecules (1‑3). Human Desmoglein-3 is synthesized with a 26 amino acid (aa) propeptide. The mature protein consists of a 566 aa extracellular domain (ECD) that contains four cadherin-like domains, a 25 aa transmembrane segment, and a 359 aa cytoplasmic domain (4). Within the ECD, human Desmoglein-3 shares 78% aa sequence identity with mouse and rat Desmoglein-3. It shares 44%, 47%, and 56% aa sequence identity with Desmoglein-1, -2, and -4 respectively. Desmoglein-3 is one of the principal components of desmosomes which form adhesive contacts between epithelial cells (1, 2). It is expressed in the basal and suprabasal layers of stratified epithelia in many tissues (4‑6). During apoptosis, Desmoglein-3 is cleaved by caspases, plus MMP-2, and MMP-9 at sites within the cytoplasmic and extracellular regions, resulting in shortened transmembrane forms and a soluble 75 kDa ECD fragment (7, 8). The downregulation of Desmoglein-3 in oral squamous cell carcinoma correlates with metastatic potential (9). Desmoglein-3 is the target of autoantibodies in pemphigus vulgaris, a blistering skin disorder with compromised inter-keratinocyte adhesion (6, 10). Binding of these antibodies triggers Desmoglein-3 internalization and degradation by keratinocytes (10).

1. Kottke, M.D. et al. (2006) J. Cell Sci. 119:797.
2. Garrod, D.R. et al. (2002) Mol. Membr. Biol. 19:81.
3. Leckband, D. and A. Prakasam (2006) Annu. Rev. Biomed. Eng. 8:259.
4. Amagai, M. et al. (1991) Cell 67:869.
5. Silos, S.A. et al. (1996) J. Biol. Chem. 271:17504.
6. Amagai, M. et al (1996) J. Invest. Dermatol. 106:351.
7. Weiske, J. et al. (2001) J. Biol. Chem. 276:41175.
8. Cirillo, N. et al. (2007) Oral Dis. 13:341.
9. Wang, L. et al. (2007) Virchows Arch. Sept. 11 epub.
10. Calkins, C.C. et al. (2006) J. Biol. Chem. 281:7623.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Desmoglein-3 Antibody (MAB1720)(7)

Publications using MAB1720

• Mohamed Sharafeldin, Tianqi Chen, Gulsum Ucak Ozkaya, Dharamainder Choudhary, Alfredo A. Molinolo, J. Silvio Gutkind et al. Detecting cancer metastasis and accompanying protein biomarkers at single cell levels using a 3D-printed microfluidic immunoarray Biosensors and Bioelectronics 2021-01-01 [PMID: 33096435]
• S Bunbanjerd, N Vorasan, T Saethang, T Pongrujiko, D Pangpunyak, N Mongkonsir, L Arsa, N Thokanit, W Pongsapich, T Anekpurita, N Ngamphaibo, A Jinawath, S Sunpawerav, T Pisitkun, B Suktitipat, N Jinawath Oncoproteomic and gene expression analyses identify prognostic biomarkers for second primary malignancy in patients with head and neck squamous cell carcinoma Mod. Pathol., 2019-02-08;0(0):. 2019-02-08 [PMID: 30737471] (IHC-P, Human)
• T Sumitomo, Y Mori, Y Nakamura, M Honda-Ogaw, S Nakagawa, M Yamaguchi, H Matsue, Y Terao, M Nakata, S Kawabata Streptococcal Cysteine Protease-Mediated Cleavage of Desmogleins Is Involved in the Pathogenesis of Cutaneous Infection Front Cell Infect Microbiol, 2018-01-24;8(0):10. 2018-01-24 [PMID: 29416987] (Western Blot, Human)
• Y Horimasu, N Ishikawa, M Taniwaki, K Yamaguchi, K Hamai, H Iwamoto, S Ohshimo, H Hamada, N Hattori, M Okada, K Arihiro, Y Ohtsuki, N Kohno Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets BMC Med. Genet., 2017-08-18;18(1):88. 2017-08-18 [PMID: 28821283] (IHC-Fr, Human)
• Vyomesh Patel, Daniel Martin, Ruchika Malhotra, Christina A. Marsh, Colleen L. Doçi, Timothy D. Veenstra et al. DSG3 as a biomarker for the ultrasensitive detection of occult lymph node metastasis in oral cancer using nanostructured immunoarrays Oral Oncology 2013-02-01 [PMID: 23010602] (Immunohistochemistry, Human)
• Chernyavsky AI, Arredondo J, Vetter DE, Grando SA Central role of alpha9 acetylcholine receptor in coordinating keratinocyte adhesion and motility at the initiation of epithelialization. Exp. Cell Res., 2007-07-20;313(16):3542-55. 2007-07-20 [PMID: 17706194] (Western Blot, Human)
• Chernyavsky AI, Arredondo J, Kitajima Y, Sato-Nagai M, Grando SA Desmoglein versus non-desmoglein signaling in pemphigus acantholysis: characterization of novel signaling pathways downstream of pemphigus vulgaris antigens. J. Biol. Chem., 2007-03-07;282(18):13804-12. 2007-03-07 [PMID: 17344213] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: DSG3
• Uniprot:
  • P32926()